Myriad Genetics Inc (MYGN) Reports 11% Revenue Growth in Q4 and Full-Year 2023
Company Raises 2024 Revenue Guidance and Delivers Positive Adjusted EPS in Q4
Stay updated with breaking news from Intermountain Precision Genomics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company Raises 2024 Revenue Guidance and Delivers Positive Adjusted EPS in Q4
SALT LAKE CITY, Feb. 01, 2024 -- Myriad Genetics, Inc., , a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select...
SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
According to marketresearch.biz, advancements in genomic studies, driven by technologies like next-generation sequencing (NGS) and microarrays, are...
SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, part of the Intermountain